Systemic Mastocytosis Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 8+ Companies and 8+ Therapies | DelveInsight

DelveInsight's, "Systemic Mastocytosis Pipeline Insight, 2025," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Systemic Mastocytosis pipeline landscape. It covers the Systemic Mastocytosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Systemic Mastocytosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Systemic Mastocytosis Pipeline. Dive into DelveInsight's comprehensive report today! @ Systemic Mastocytosis Pipeline Outlook [https://www.delveinsight.com/sample-request/systemic-mastocytosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Systemic Mastocytosis Pipeline Report

* In May 2025, M.D. Anderson Cancer Center announced a clinical research study is to see if RAD001 can help to control the disease in patients with systemic mastocytosis (SM). The safety of this treatment will also be studied. RAD001 is designed to stop cancer cells from multiplying. It may also stop the growth of new blood vessels that help tumor growth, which may cause the tumor cells to die.
* In May 2025, Cogent Biosciences Inc . announced a Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
* DelveInsight's Systemic Mastocytosis Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Systemic Mastocytosis treatment.
* The leading Systemic Mastocytosis Companies such as AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology and others.
* Promising Systemic Mastocytosis Pipeline Therapies such as PA101, Avapritinib, RAD001 (Everolimus), Elenestinib, Masitinib, Avapritinib, Brentuximab vedotin, TL-895 and others.

Stay ahead with the most recent pipeline outlook for Systemic Mastocytosis. Get insights into clinical trials, emerging therapies, and leading companies with Systemic Mastocytosis @ Systemic Mastocytosis Treatment Drugs [https://www.delveinsight.com/sample-request/systemic-mastocytosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Systemic Mastocytosis Emerging Drugs Profile

* Avapritinib: Blueprint Medicines

Avapritinib is a potent and selective inhibitor of activated KIT and PDGFRA mutant kinases. In certain diseases, mutations in KIT and PDGFRA force protein kinases into an increasingly active state. Avapritinib is uniquely designed to bind and inhibit the active conformation of these proteins. Blueprint Medicines is developing AYVAKIT globally for the treatment of advanced and indolent SM. Blueprint Medicines has an exclusive collaboration and license agreement with CStone Pharmaceuticals for the development and commercialization of AYVAKIT in Mainland China, Hong Kong, Macau and Taiwan. Blueprint Medicines retains development and commercial rights for AYVAKIT in the rest of the world. The FDA granted breakthrough therapy designation to AYVAKIT for the treatment of advanced SM, including the subtypes of aggressive SM, SM with an associated hematological neoplasm and mast cell leukemia, and for the treatment of moderate to severe indolent SM. The FDA has accepted a supplemental new drug application for avapritinib for the treatment of advanced SM. The European Medicines Agency has validated a Type II variation marketing authorization application for avapritinib for the treatment of advanced SM.

* Masitinib: AB Sciences

Masitinib's anti-mast cell properties appear particularly well-adapted to the treatment of indolent systemic mastocytosis. A reduction of mast cell activity is generated via its inhibitory action on wild-type c-Kit, Lyn and Fyn tyrosine kinases. In recognition of the critical need for new treatments, masitinib received orphan drug designation for mastocytosis from both the European Medicine Agency (EMA) and the U.S. Food and Drug Administration (FDA). AB Science initiated a confirmatory phase 3 study, with design optimized based on findings from the first phase 3 study.

The Systemic Mastocytosis Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Systemic Mastocytosis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Systemic Mastocytosis Treatment.
* Systemic Mastocytosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Systemic Mastocytosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Systemic Mastocytosis market

Explore groundbreaking therapies and clinical trials in the Systemic Mastocytosis Pipeline. Access DelveInsight's detailed report now! @ New Systemic Mastocytosis Drugs [https://www.delveinsight.com/sample-request/systemic-mastocytosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Systemic Mastocytosis Companies

AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology and others.

Systemic Mastocytosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
* Molecule Type

Systemic Mastocytosis Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type

Unveil the future of Systemic Mastocytosis Treatment. Learn about new drugs, Systemic Mastocytosis Pipeline developments, and key companies with DelveInsight's expert analysis @ Systemic Mastocytosis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/systemic-mastocytosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Systemic Mastocytosis Pipeline Report

* Coverage- Global
* Systemic Mastocytosis Companies- AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology and others.
* Systemic Mastocytosis Pipeline Therapies- PA101, Avapritinib, RAD001 (Everolimus), Elenestinib, Masitinib, Avapritinib, Brentuximab vedotin, TL-895 and others.
* Systemic Mastocytosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Systemic Mastocytosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Systemic Mastocytosis Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Systemic Mastocytosis Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/systemic-mastocytosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Systemic Mastocytosis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Systemic Mastocytosis - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Systemic Mastocytosis Collaboration Deals
* Late Stage Products (Preregistration)
* Avapritinib: Blueprint Medicines
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* PA101: Patara Pharma
* Drug profiles in the detailed report.....
* Early stage products (Phase I)
* DCC-2618: Deciphera Pharmaceuticals
* Drug profiles in the detailed report.....
* Inactive Products
* Systemic Mastocytosis Key Companies
* Systemic Mastocytosis Key Products
* Systemic Mastocytosis- Unmet Needs
* Systemic Mastocytosis- Market Drivers and Barriers
* Systemic Mastocytosis- Future Perspectives and Conclusion
* Systemic Mastocytosis Analyst Views
* Systemic Mastocytosis Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=systemic-mastocytosis-clinical-trial-analysis-key-insights-into-rich-pipeline-featuring-8-companies-and-8-therapies-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/systemic-mastocytosis-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.